| Project/Area Number |
16K18873
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | アデノウイルスベクター / 粘膜ワクチン / Th17 / Type I IFN / 炎症性樹状細胞 / 炎症性単球 / 自然免疫 |
|---|
| Outline of Final Research Achievements |
Few of the current vaccines can induce antigen (Ag)-specific immunity in both mucosal and systemic compartments. Hence, the development of vaccines that realize both protections against various pathogens is a high priority in global health. It was reported that intramuscular vaccination of an adenovirus vector (Adv) can induce Ag-specific cytotoxic T lymphocytes (CTLs) in both systemic and gut-mucosal compartments. We previously revealed that type I IFN signaling is required for the induction of gut-mucosal, not systemic, CTLs, following the vaccination. Here, we revealed that type I IFN is required for the induction of Ag-specific Th17 cells, which could promote the induction of Ag-specific CTLs selectively in the gut mucosa. These data suggested that Th17 cells translate systemic type I IFN into gut-mucosal CTL response following the vaccination. Our findings should lead to the development of promising Adv vaccines that can establish both systemic and gut-mucosal protective immunity.
|
